Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Marseille
Clinical trial register · France

Clinical Trials in Marseille, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC
9697
Studies in scope
all four open statuses
6025
Recruiting now
open to new participants
1033
Lead sponsors
across recruiting studies
Top sites
Paris 46 Marseille 37 Toulouse 32 Bordeaux 29 Lille 23
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Assistance Publique Hopitaux De Marseille91 AstraZeneca58 Institut Paoli-Calmettes40 Merck Sharp & Dohme LLC37 Novartis Pharmaceuticals36 Clear sponsor filter
Site location
Paris46 Marseille37 Toulouse32 Bordeaux29 Lille23
All 72 locations
Target enrolment
to

Trials with a site in Marseille

37 of 9697 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Nice, Marseille, Toulouse, Angers, Le Mans, Saint Priest En Jarez, Villejuif
2026-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Lyon, Strasbourg, Marseille, Plérin, Brest, Toulouse, Limoges, Tours
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Marseille, Caen, Vandœuvre-lès-Nancy, Pau, Chambéry, Amiens, Paris
2025-10-08
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Marseille, Dijon, Saint-Cloud, Montpellier, Rennes, Pierre-Bénite, Amiens, Créteil
2025-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Bordeaux, Marseille, Nantes, Lyon, Paris
2025-05-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Marseille, Caen, Plérin, Bordeaux, Toulouse, Saint-Cloud, Saint-Herblain, Lyon
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Suresnes, Strasbourg, Marseille, Caen, Besançon, Nîmes, Limoges, Vandœuvre-lès-Nancy
2025-05-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Pessac, Marseille, Rouen, Clermont-Ferrand
2025-05-12
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Marseille, Rennes, Lille, Villejuif
2025-03-25
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Bordeaux, Lyon, Nantes, Marseille, Villejuif
2024-08-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Bordeaux, Lyon Cedex08, Clermont-Ferrand, Strasbourg, Marseille, Plérin, Besançon, Toulouse
2024-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Nice, Pessac, Marseille, Toulouse, Limoges, Tours, Nantes, Pierre-Bénite
2024-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Nice, Bayonne, Guilherand-Granges, Lyon Cedex08, Clermont-Ferrand, Marseille, Caen, Dijon
2024-06-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Strasbourg, Marseille, Paris, Villejuif
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Marseille, Vantoux, Angers, Avignon, La Roche-sur-Yon, Paris
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nice, Pessac, Marseille, Dijon, Reims, Besançon, Valence, Nîmes
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Marseille, Montpellier, Limoges, Nancy, Bayonne, Villefranche-sur-Saône, Amiens, Poitiers
2023-12-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Strasbourg, Pessac, Marseille, Caen, Montpellier, Angers, Clermont-Ferrand, Paris
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Nice, Pessac, Marseille, Reims, Besançon, Nîmes, Clichy, Neuilly-sur-Seine
2023-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Nice, Marseille, Dijon, Besançon, Bordeaux, Rennes, Lille, Pierre-Bénite
2023-07-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
Pessac, Nantes, Lille, Marseille, Paris
2023-05-31
Active, closed
Merck Sharp & Dohme LLC
Phase 2
129
Marseille, Vandœuvre-lès-Nancy, Angers, Le Kremlin-Bicêtre, Poitiers
2023-03-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
42
Toulouse, Marseille, Paris
2023-01-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Marseille, Toulouse, Limoges
2022-03-24
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Strasbourg, Lyon, Marseille, Le Kremlin-Bicêtre, Paris, Villejuif
2021-08-12
Active, closed
Merck Sharp & Dohme LLC
Phase 2
302
Marseille, Dijon, Toulouse, Lille, Poitiers, Paris
2021-06-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Lyon, Marseille, Caen, Besançon, Toulouse, Montpellier, Saint-Herblain, Angers
2021-06-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Marseille, Besançon, Brest, Toulouse, Limoges, La Tronche, Orléans, Lille
2021-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Marseille, Besançon, Toulouse, Limoges, Beuvry, Angers, Pierre-Bénite, Paris
2021-04-14
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Nice, Pierre-Bénite, Marseille, Le Chesnay, Paris
2021-04-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Saint-Quentin, Bordeaux, Marseille, Grenoble, Saint-Herblain, Angers, Bobigny, Toulon
2020-12-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Marseille, Brest, Epagny Metz Tessy, Valenciennes, Bobigny, Amiens, Toulon, La Roche-sur-Yon
2020-07-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Marseille, Dijon, Caen, Besançon, Nîmes, Bordeaux, Toulouse, Montpellier
2019-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Nice, Marseille, Toulouse, Villejuif, Avignon, Paris
2018-12-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Marseille, Dijon, Bordeaux, Toulouse, Boulogne-Billancourt, Montpellier, Rennes, Angers
2018-09-12
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Nice, Strasbourg, Pessac, Pierre-Bénite, Lyon, Marseille, Caen, Dijon
2018-08-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
340
Lyon, Marseille, Bordeaux, Lille, Villejuif, Paris
2018-04-09
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 October 2026. https://priyalifescience.com/clinical-trials-france/city/marseille

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies with a site in Marseille that also match the filters currently applied.

How many clinical trials are recruiting in Marseille?

18 of the 37 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Marseille), 37 studies
PhaseStudiesRecruitingShare
Phase 3261170.3%
Phase 27318.9%
Phase 1/2338.1%
Phase 2/3112.7%

Most active sponsors

Lead sponsors with the most studies (Marseille)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC3718
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.